September 20, 2021
FDA committee votes against COVID-19 vaccine boosters for general population
Editor's Note
The Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee on September 17 voted that there was not enough safety and effectiveness data to approve a third Pfizer COVID-19 vaccine dose for those 16 years and older.
The committee did vote to recommend approval of a booster dose for people 65 years and older and those at high risk of severe COVID-19.
The committee also recommended approval of a booster for those with occupational risks, such as healthcare workers and teachers.
Free Daily News
- Healthcare job gain in August offset by losses in federal government, other industries
- AHA study: HOPD Medicare patients are poorer, sicker, more rural than those seen in physician offices
- ACS, Lifesaving Technologies launch nationwide effort to expand bleeding control readiness
- Minimally invasive ICH surgery evacuates clot fast but fails to improve 6-month outcomes
- Rural hospitals face crisis under OBBBA as experts call for cohesive reform
- AMA urges health systems to act now on AI governance
- Suicide Prevention Month: Hospitals prepare for new The Joint Commission suicide prevention goal, effective 2026
- Survey: Perioperative leaders adapt to supply strain, staffing pressure, ASC growth
- Gait retraining eases knee osteoarthritis pain as effectively as medication, can delay knee surgery
- OR leaders must sharpen questions, partnerships as AI reshapes perioperative care
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement